公开(公告)号：US20230158073A1

公开(公告)日：2023-05-25

申请号：US17919135

申请日：2021-04-16

Applicant: Cancer Research Technology Limited

Inventor： Sergio Quezada ,  Karl Peggs ,  Charles Swanton ,  Ehsan Ghorani ,  James Reading ,  Felipe Galvez-Cancino ,  Despoina Karagianni

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00

Abstract: The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3. Further provided are activity modulators of one or more proteins encoded by genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3 for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or inhibitor.